3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Genitourinary
2
Dermatologic
2
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
CNS
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Interventions
Carboplatin
181
pembrolizumab
156
Pemetrexed
129
Cisplatin
97
Drug Therapy
67
Paclitaxel
59
osimertinib
56
Magnetic Resonance Spectroscopy
50
durvalumab
49
Specimen Handling
49
Radiotherapy
49
Nivolumab
49
atezolizumab
43
Docetaxel
43
Etoposide
40
Bevacizumab
39
Blood Specimen Collection
33
tislelizumab
31
Radiosurgery
31
Gemcitabine
29
130-nm albumin-bound paclitaxel
27
Immunotherapy
25
Immune Checkpoint Inhibitors
25
cemiplimab
23
Injections
23
aflutinib
20
Cetuximab
18
Biopsy
18
Standard of Care
17
Platinum Compounds
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Solutions
×
Thoracic
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled